Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 9, Issue 7, 2009, Pages 909-919

  Bracewell, C ^a   Isaacs, J D ^a   Emery, P ^b   Ng, W F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Atacicept; B cells; Biological therapies; Growth factors; Rheumatoid arthritis

Indexed keywords

ATACICEPT; BELIMUMAB; EPRATUZUMAB; IMMUNOGLOBULIN; METHOTREXATE; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; HUMAN; INFECTION; INJECTION SITE CONTUSION; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PNEUMOTHORAX; PRURITUS; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SINGLE DRUG DOSE; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS;

EID: 67650388093     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903033919     Document Type: Review

References (51)

1. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2006;65(Suppl 3):2-15
2. Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore 2007;36:128-134 • A review of current pharmacological treatments for rheumatoid arthritis highlighting the recent advances in biological therapies.
3. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-610 (Pubitemid 44650948)
4. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor aα therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-2904 (Pubitemid 47502735)
5. Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246-252 • A review outlining the important role of B cells in rheumatoid arthritis and implications for targeted B cell therapies.
6. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford 2005;44(Suppl 2):3-7
7. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-928 (Pubitemid 44382384)
8. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29 (Suppl 2):105-112 (Pubitemid 34173032)
9. Tanaka Y. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern Med 2007;46:1313-1315
10. Roche Products Limited. Mabthera 100 mg and 500mg concentrate for solution for infusion. Available from: http://emc.medicines.org.uk/medicine/ 2570/SPC/Mabthera + 100mg + and + 500mg + concentrate + for + solution + for + infusion/ [Last accessed on 22 May 2009]
11. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-211 (Pubitemid 32229642)
12. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, PhaseIII trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806 • Efficacy and safety results from a PhaseIII study of rituximab, the first licensed B cell-depleting therapy, and methotrexate in the treatment of patients with active rheumatoid arthritis who had an inadequate response to previous anti-TNF therapies are reported.
13. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-732 • A study showing that rituximab treatment in some patients with rheumatoid arthritis increases B lymphocyte stimulator levels, which may contribute to the survival of B cell populations and subsequent clinical episodes.
14. De Vita S, Zaja F, Sacco S, etal. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-2033
15. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581 (Pubitemid 38758544)
16. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-620 (Pubitemid 43228639)
17. Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007;46:29-36 (Pubitemid 44932780)
18. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-221
19. Därner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008;20:263-268
20. Roque R, Ponce R, Burleson F, et al. Influenza virus host response of C57Bl/6 mice treated with TACI-Ig. Immunopharmacol Immunotoxicol 2006;28:13-32 (Pubitemid 43739106)
21. Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-4321 •• A study indicating that BLyS and APRIL play a role in autoimmune disease as active BLyS-APRIL heterotrimers were identified in the sera of patients with systemic immune-based rheumatic disease.
22. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-317
23. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302 •• An important preclinical study with a murine model of rheumatoid arthritis, which provided evidence for the role of BLyS and APRIL in modulating B cell development and demonstrated that atacicept was able to inhibit the progression of disease.
24. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-817 (Pubitemid 38924255)
25. Zhang X, Park CS, Yoon SO, et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005;17:779-788
26. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180:3655-3659 •• A study showing that simultaneous inhibition of BLyS and APRIL is required to decrease bone marrow plasma cells but has no effect on memory B cell survival and function.
27. Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 2008;105:200-210
28. Kalled SL. BAFF: a novel therapeutic target for autoimmunity. Curr Opin Investig Drugs 2002;3:1005-1010 (Pubitemid 36266787)
29. Gross JA, Johnston J, Mudri S, etal. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-999 •• A study which identified the BlyS-binding TACI receptor, its role in B cell autoimmune disease and the potential use of TACI-Ig as a treatment for autoimmune disease.
30. Stohl W, Metyas S, Tan SM, etal. Inverse assoication between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63(9):1096-1103
31. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115(11):3083-3092
32. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 2008;8:1805-1814
33. Seshasayee D, Valdez P, Yan M, etal. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-288
34. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-1710 (Pubitemid 30002351)
35. Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007;63:647-656 •• A PhaseI study showing that atacicept was well tolerated in healthy volunteers with non-linear pharmacokinetics and demonstrated biological activity.
36. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, PhaseIb, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72 •• A pivotal PhaseIb study showing that atacicept treatment in patients with rheumatoid arthritis was well tolerated and biological activity was demonstrated with treatment-related decreases in immunoglobulin and rheumatoid factor levels and reductions in mature B cells.
37. Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48:406-417 •• A PhaseI study analysing the pharmacokinetic and pharmocodynamic profiles of atacicept in patients with rheumatoid arthritis.
38. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-703 (Pubitemid 46707145)
39. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167. Published online 8 November 2006, doi:10.1186/ar2076
40. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, PhaseIb, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-4150 (Pubitemid 350262342)
41. Ansell SM, Witzig TE, Inwards DJ, et al. PhaseI clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105-1110 (Pubitemid 351302557)
42. Rossi J-F, Moreaux J, Rose M, etal. A PhaseI/II study of atacicept, an inhibitor of APRIL and BLyS, in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) [Abstract PO-601]. Haematologica 2007;92(Suppl 2):153
43. La DT, Collins CE, Yang HT, et al. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor aα antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 2008;67:1132-1138 • A report showing that good clinical responses with anti-TNF therapies in patients with rheumatoid arthritis are associated with decreases in BLyS levels but similar decreases were not observed in poor responders to anti-TNF therapy indicating that inhibition of BLyS may be beneficial in patients who do not respond to anti-TNF therapies.
44. Genovese MC, Kaine JL, Kohen MD, et al. Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20 + B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Ph I/II ACTION study) [Abstract #6]. Arthritis Rheum 2006;54(Suppl 9):S66
45. OØstergaard M, Wiell C, Sierakowski S, et al. HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis [Abstract #2122]. Arthritis Rheum 2006;54(9 Suppl):S230
46. Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-1067 (Pubitemid 40909524)
47. Mckay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard care of therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population [Abstract 1920]. Arthritis Rheum 2005;52(Suppl 9):S710-1
48. Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009;37:89-99
49. Darce JR, Arendt BA, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-7286
50. Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-4398 (Pubitemid 40720786)
51. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65(Suppl 3):34-36 (Pubitemid 44629099)